Neupro's Multicenter and Prospective Observation of Safety and Efficacy in Chinese Mainland Idiopathic Parkinson's Disease in Real World Practice

Parkinson's disease (PD) is a long-term, chronic, progressive and disabling disease, which affects millions of patients worldwide. The incidence rate of Parkinson's disease is about 20/100000 per year. With the increase of age (65 years old and above), the incidence rate of the population increased significantly, reaching >100/100000 per year . The average age of onset is 58 to 62 years old, and the prevalence rate of people over 50 years old is about 1%. Similar to the incidence rate, the prevalence of Parkinson's disease increases with age. It is 1.4% at 55 years old, and 4.3% in 85 years old and above.

The main clinical symptoms of Parkinson's disease include tremor, myotonia, motor retardation, postural reflex disorders and gait disorders, as well as a variety of other motor, mental, sensory and autonomic neuropathy. Depressive symptoms of Parkinson's disease are very common in patients. In the progressive stage of the disease, patients may have dementia symptoms. Autonomic nervous system involvement may cause orthostatic hypotension, paroxysmal flushing, thermoregulation disorders, constipation, dysphagia, bladder and sexual dysfunction. Involvement of dopaminergic pathways in the thalamus and spinal cord may lead to sensory abnormalities.

The etiology of Parkinson's disease remains unclear. However, it is generally considered to be a progressive degenerative disease, which gradually erodes the brain stem, basal ganglia structure and its projection system. Pathological studies have found that there are loss of dopaminergic neurons in substantia nigra and neurons in locus coeruleus and raphe nucleus, deposition of Lewy bodies and activation of glial cells. Basic studies suggest that oxidative damage of specific neurons in basal ganglia is one of the potential causes of idiopathic Parkinson's disease, and aging and genetic factors are also the main causes of the disease

Predisposing factors.

Rotigotine ((6S) - 6 - {propyl [2 - (2-thienyl) ethyl] amino} - 5,6,7,8-tetrahydro-1-naphthol) is the left-handed enantiomer of chiral aminotetrahydronaphthalene compounds. Rotigotine is a dopamine receptor agonist. Its dosage form is designed as a transdermal drug delivery system, which can continuously release rotigotine within 24 hours. Transdermal drug delivery system, which continuously releases dopamine receptor agonists (such as rotigotine) in a non-invasive manner. Rotigotine has been approved by global health agencies for the treatment of early and advanced Parkinson's disease. Overall, ushib or authorized partners have market licenses for rotigotine transdermal patches for Parkinson's disease in 70 countries. A detailed description of the preclinical and clinical experience of rotigotine can be found in the investigator's manual.